Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for crohn's disease

Katsuyoshi Matsuoka, Takanori Kanai

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It is not too much to say that infliximab has revolutionized the treatment of Crohn's disease. However, there is the problem of 'secondary failure' wherein the effect may diminish during treatment. This is a much-discussed topic. For example, not all patients with secondary failure can maintain remission with dose intensification to 10 mg/kg. It is also important to make the appropriate drug selection and to clarify the optimal timing of dose intensification for achieving long-term maintenance of remission, including discussion of the first priority use of adalimumab.

Original languageEnglish
Pages (from-to)17-19
Number of pages3
JournalDigestion
Volume88
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Crohn Disease
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Therapeutics
Pharmaceutical Preparations
Infliximab
Adalimumab

Keywords

  • Biologics
  • Crohn's disease
  • Inflammatory bowel disease
  • Infliximab
  • Secondary failure

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for crohn's disease. / Matsuoka, Katsuyoshi; Kanai, Takanori.

In: Digestion, Vol. 88, No. 1, 2013, p. 17-19.

Research output: Contribution to journalArticle

@article{b5705753a7ce421292fd95c603005e1f,
title = "Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for crohn's disease",
abstract = "It is not too much to say that infliximab has revolutionized the treatment of Crohn's disease. However, there is the problem of 'secondary failure' wherein the effect may diminish during treatment. This is a much-discussed topic. For example, not all patients with secondary failure can maintain remission with dose intensification to 10 mg/kg. It is also important to make the appropriate drug selection and to clarify the optimal timing of dose intensification for achieving long-term maintenance of remission, including discussion of the first priority use of adalimumab.",
keywords = "Biologics, Crohn's disease, Inflammatory bowel disease, Infliximab, Secondary failure",
author = "Katsuyoshi Matsuoka and Takanori Kanai",
year = "2013",
doi = "10.1159/000351386",
language = "English",
volume = "88",
pages = "17--19",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for crohn's disease

AU - Matsuoka, Katsuyoshi

AU - Kanai, Takanori

PY - 2013

Y1 - 2013

N2 - It is not too much to say that infliximab has revolutionized the treatment of Crohn's disease. However, there is the problem of 'secondary failure' wherein the effect may diminish during treatment. This is a much-discussed topic. For example, not all patients with secondary failure can maintain remission with dose intensification to 10 mg/kg. It is also important to make the appropriate drug selection and to clarify the optimal timing of dose intensification for achieving long-term maintenance of remission, including discussion of the first priority use of adalimumab.

AB - It is not too much to say that infliximab has revolutionized the treatment of Crohn's disease. However, there is the problem of 'secondary failure' wherein the effect may diminish during treatment. This is a much-discussed topic. For example, not all patients with secondary failure can maintain remission with dose intensification to 10 mg/kg. It is also important to make the appropriate drug selection and to clarify the optimal timing of dose intensification for achieving long-term maintenance of remission, including discussion of the first priority use of adalimumab.

KW - Biologics

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - Infliximab

KW - Secondary failure

UR - http://www.scopus.com/inward/record.url?scp=84879143699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879143699&partnerID=8YFLogxK

U2 - 10.1159/000351386

DO - 10.1159/000351386

M3 - Article

C2 - 23797247

AN - SCOPUS:84879143699

VL - 88

SP - 17

EP - 19

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 1

ER -